Table 5.
Multivariate analysis for Relapse, NRM, LFS, OS, and GRFS
| Relapse | NRM | LFS | OS | GRFS | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | HR (95% CI) | p value | |
| ATG vs PTCy | 0.93 (0.63–1.37) | 0.71 | 1.04 (0.65–1.66) | 0.86 | 0.98 (0.74–1.29) | 0.86 | 0.94 (0.7–1.27) | 0.71 | 0.89 (0.7–1.13) | 0.35 |
| Age (per 10 years) | 1.01 (0.92–1.11) | 0.9 | 1.37 (1.2–1.56) | < 10–5 | 1.13 (1.05–1.22) | 0.001 | 1.21 (1.12–1.32) | < 10–5 | 1.06 (1–1.14) | 0.07 |
| sec. AML vs de novo | 1.14 (0.86–1.53) | 0.36 | 1.39 (1.02–1.9) | 0.04 | 1.24 (1.01–1.53) | 0.04 | 1.29 (1.03–1.6) | 0.02 | 1.25 (1.03–1.52) | 0.02 |
| Adverse cytogenetics vs other | 1.77 (1.41–2.24) | < 10–5 | 1.19 (0.88–1.61) | 0.27 | 1.51 (1.26–1.81) | < 10–5 | 1.42 (1.17–1.72) | 0.0004 | 1.36 (1.15–1.61) | 0.0003 |
| Female donor-male recipient vs other | 0.54 (0.36–0.8) | 0.002 | 1.46 (1.04–2.05) | 0.03 | 0.89 (0.69–1.15) | 0.38 | 0.93 (0.71–1.22) | 0.6 | 1.11 (0.89–1.38) | 0.35 |
| RIC vs MAC | 1.06 (0.82–1.36) | 0.66 | 0.84 (0.63–1.13) | 0.25 | 0.97 (0.81–1.17) | 0.75 | 0.91 (0.74–1.11) | 0.33 | 0.98 (0.83–1.15) | 0.77 |
| KPS ≥ 90 | 1.16 (0.9–1.51) | 0.26 | 0.85 (0.64–1.13) | 0.27 | 1.02 (0.84–1.23) | 0.86 | 0.98 (0.81–1.2) | 0.87 | 0.96 (0.81–1.13) | 0.60 |
| Patient CMV positivity | 0.99 (0.79–1.24) | 0.92 | 1.31 (0.99–1.73) | 0.06 | 1.11 (0.93–1.32) | 0.24 | 1.12 (0.93–1.35) | 0.22 | 1.11 (0.95–1.29) | 0.21 |
| Donor CMV positivity | 1.17 (0.94–1.45) | 0.16 | 1 (0.77–1.3) | 0.98 | 1.09 (0.92–1.28) | 0.33 | 1.09 (0.91–1.3) | 0.34 | 1.11 (0.96–1.29) | 0.16 |
| Year of transplantation | 1.04 (0.99–1.1) | 0.12 | 1 (0.94–1.07) | 0.99 | 1.02 (0.98–1.07) | 0.26 | 1.02 (0.98–1.07) | 0.37 | 1.03 (1–1.07) | 0.07 |
| PBSC vs BM | 0.96 (0.68–1.36) | 0.82 | 1.29 (0.8–2.09) | 0.29 | 1.05 (0.8–1.39) | 0.73 | 1.11 (0.82–1.49) | 0.50 | 1.14 (0.88–1.47) | 0.31 |
Abbreviations: AML acute myeloid leukemia, ATG antithymocyte globulin, BM bone marrow, CI confidence interval, CMV cytomegalovirus, cGVHD chronic graft-versus-host disease, Ext extensive, GRFS graft-versus-host disease-free, relapse-free survival, HR hazard ratio, KPS Karnofsky Performance Status, LFS leukemia-free survival, MAC myeloablative conditioning regimen, NRM non-relapse mortality, OS overall survival, PBSC peripheral blood stem cell, PTCY post-transplantation cyclophosphamide, RIC reduced intensity conditioning regimen, sec.AML secondary acute myeloid leukemia